Tumor type | EVs type | Content of chemokines | Role of Evs | References |
---|---|---|---|---|
Breast cancer | MVs | CCL5, CCR6 | metastasis, proliferation and cancer cell-induced angiogenesis | |
Colorectal adenocarcinoma | MVs | CCR6, CX3CR1, CCL2 | antiapoptotic effect on monocytes, AKT kinase activation,proliferation | |
Gastric cancer | MVs | CCR6 | tumor progression | [52] |
Glioblastoma | EVs | CCR8, CCL18 | proliferation and drug resistance | [56] |
Haemophilia A | MVs | CXCL8, CXCL10, CCL2 | immunological profile | [36] |
Leukemia | Apoptotic blebs | CCR7, CCL19 | immuno modulation | [50] |
 | Exsomoes | CCL3, CCL4, CXCR4 | cell survival and drug resistance | [74] |
 | MVs | CXCR4, CCL12 | cell survival | [68] |
Lung carcinoma | MVs | CCR6, CX3CR1, CXCR4 | metastasis, antiapoptotic effect on monocytes, AKT kinase activation | |
 | Exsomoes | CCL2, CCL3, CCL4, CCL5, CCL20 | antitumor immune response | [51] |
Lymphoma | Exosomes | CCL2, CCL7 | macrophage recruitment | [42] |
Melanoma | Exosomes | CCL2, CCL3, CCL4, CCL5, CCL7, CCL20 | macrophage recruitment, antitumor immune response | |
 | MVs | CCL2 | inhibi ttumor proliferation | [49] |
Pancreatic adenocarcinoma | MVs | CCR6, CX3CR1, CCL2, CCL3, CCL4, CCL5, CXCL8 | anti-apoptosis, AKT kinase activation, angiogenesis | |
Prostate cancer | Oncosomes | CXCL12 | oncogenic signaling | [23] |